PY2471990A - Compuesto moduladores de pde 7 - Google Patents

Compuesto moduladores de pde 7

Info

Publication number
PY2471990A
PY2471990A PY202402471990A PY2471990A PY2471990A PY 2471990 A PY2471990 A PY 2471990A PY 202402471990 A PY202402471990 A PY 202402471990A PY 2471990 A PY2471990 A PY 2471990A PY 2471990 A PY2471990 A PY 2471990A
Authority
PY
Paraguay
Prior art keywords
pde
ring
compounds
modulator compound
disclosed
Prior art date
Application number
PY202402471990A
Other languages
English (en)
Inventor
Neil S Cutsall
Mark A Hadd
Santosh Kumar Keshipeddy
Robert H Lemus
Markus Metz
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of PY2471990A publication Critical patent/PY2471990A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer compuestos que poseen actividad como moduladores de la fosfodiesterasa 7 (PDE 7). Los compuestos poseen las siguientes Estructuras (I) o (II): como un estereoisómero, enantiómero, o tautómero del mismo o una mezcla de los mismos; o una sal, solvato o profármaco farmacéuticamente aceptable de los mismos, donde cada uno de R1, R2, R3, R4a, R4b, el anillo A, el anillo B, el anillo A' el anillo B' tales como se muestran en las Estructuras (I) y (II), respectivamente son tal como se definen en la presente memoria. También se dan a conocer métodos asociados con la preparación y uso de tales compuestos, composiciones farmacéuticas que comprenden tales compuestos y métodos para modular la actividad de la fosfodiesterasa 7 (PDE 7).
PY202402471990A 2023-08-22 2024-08-21 Compuesto moduladores de pde 7 PY2471990A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363578039P 2023-08-22 2023-08-22

Publications (1)

Publication Number Publication Date
PY2471990A true PY2471990A (es) 2025-04-24

Family

ID=92712604

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202402471990A PY2471990A (es) 2023-08-22 2024-08-21 Compuesto moduladores de pde 7

Country Status (8)

Country Link
US (1) US20250066383A1 (es)
CN (1) CN121941676A (es)
AR (1) AR133604A1 (es)
AU (1) AU2024328083A1 (es)
IL (1) IL326719A (es)
PY (1) PY2471990A (es)
TW (1) TW202523670A (es)
WO (1) WO2025042956A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2006004040A1 (ja) * 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体

Also Published As

Publication number Publication date
AU2024328083A1 (en) 2026-03-05
US20250066383A1 (en) 2025-02-27
AR133604A1 (es) 2025-10-15
WO2025042956A1 (en) 2025-02-27
IL326719A (en) 2026-04-01
CN121941676A (zh) 2026-04-28
TW202523670A (zh) 2025-06-16

Similar Documents

Publication Publication Date Title
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
CO2022017622A2 (es) Inhibidores de quinasa nek7
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
CL2025002997A1 (es) Derivados bicíclicos semisaturados y usos relacionados.
CO2022019131A2 (es) Inhibidores de la quinasa nek7
CL2020001817A1 (es) Moduladores del receptor c5a
PE20250791A1 (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2024012471A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
MX2024005187A (es) Nuevo compuesto espiro.
PY2471990A (es) Compuesto moduladores de pde 7
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
PE20240107A1 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos
CO2024000083A2 (es) Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
UY38488A (es) Derivados de pirazol y su uso en medicina
MX9300423A (es) Derivados heterociclicos.
CO2023012711A2 (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de nr2b
PE20221454A1 (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4
CO2024012868A2 (es) Derivado de imidazopiridazina, y método de preparación del mismo, composición farmacéutica del mismo y uso del mismo
CO2022004768A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2025017426A2 (es) Composición farmacéutica de inhibidor de csf-1r, método de preparación para esta y uso farmacéutico de esta